Helus Pharma gaps up, then fades after Barclays Overweight, $35 target
Helus Pharma (HELP) opened at $15.15 and reached a new 52-week high after Barclays initiated coverage with an Overweight rating and a $35 price target ahead of upcoming psychedelic drug trial results. By midday it was trading near $12.50.
15 and reached a new 52-week high before giving back gains after Barclays started coverage with an Overweight rating and a $35 price target ahead of upcoming trial results for its psychedelic drug. 50.